The prognostic value of long noncoding RNA SNHG16 on clinical outcomes in human cancers: a systematic review and meta-analysis

Abstract Background Cancer has been a worldwide health problem with a high risk of morbidity and mortality, however ideal biomarkers for effective screening and diagnosis of cancer patients are still lacking. Small nucleolar RNA host gene 16 (SNHG16) is newly identified lncRNA with abnormal expression in several human malignancies. However, its prognostic value remains controversial. This meta-analysis aimed to synthesize available data to clarify the association between SNHG16 expression levels and clinical prognosis value in multiple cancers. Methods Extensive literature retrieval was conducted to identify eligible studies, and data regarding SNHG16 expression levels on survival outcomes and clinicopathological features were extracted and pooled for calculation of the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Forest plots were applied to show the association between SNHG16 expression and survival prognosis. Additionally, The Cancer Genome Atlas (TCGA) dataset was screened and extracted for validation of the results in this meta-analysis. Results A total of eight studies comprising 568 patients were included in the final meta-analysis according to the inclusion and exclusion criteria. In the pooled analysis, high SNHG16 expression significantly predicted worse overall survival (OS) in various cancers (HR = 1.87, 95% CI 1.54–2.26, P < 0.001), and recurrence-free survival (RFS) in bladder cancer (HR = 1.68, 95% CI 1.01–2.79, P = 0.045). Meanwhile, stratified analyses revealed that the survival analysis method, tumor type, sample size, and cut-off value did not alter the predictive value of SNHG16 for OS in cancer patients. In addition, compared to the low SNHG16 expression group, patients with high SNHG16 expression were more prone to worse clinicopathological features, such as larger tumor size, advanced clinical stage, lymph node metastasis (LNM) and distant metastasis (DM). Exploration of TCGA dataset further validated that the upregulated SNHG16 expression predicted unfavorable OS and disease-free survival (DFS) in cancer patients. Conclusions The present study implicated that aberrant expression of lncRNA SNHG16 was strongly associated with clinical survival outcomes in various cancers, and therefore might serve as a promising biomarker for predicting prognosis of human cancers.

Download Full-text

Prognostic Value of Long Noncoding RNA SPRY4-IT1 on Survival Outcomes in Human Carcinomas: A Systematic Review and Meta-Analysis with TCGA Database

BioMed Research International ◽

10.1155/2020/5868602 ◽

2020 ◽

Vol 2020 ◽

pp. 1-14

Author(s):

Hai-mei Wang ◽

Hui-jie Li ◽

Jun-zhen Chen ◽

Ke Pei ◽

Qian Zhang ◽

...

Keyword(s):

Systematic Review ◽

Cancer Patients ◽

Long Noncoding Rna ◽

Noncoding Rna ◽

Meta Analysis ◽

Cancer Prognosis ◽

Survival Outcomes ◽

Human Cancers ◽

Human Carcinomas ◽

Tcga Dataset

Background. Emerging evidences have shown that long noncoding RNA SPRY4-IT1 can be aberrantly expressed in human cancers, and it could be an unfavorable prognostic factor in cancer patients. However, the prognostic mechanism of SPRY4-IT1 is still unclear. This study is aimed at evaluating its potential predictive value for cancer prognosis. Methods. We thoroughly searched PubMed, Embase, Web of Science, and MEDLINE databases so as to explore the relationship between SPRY4-IT1 expression and cancer prognosis value. Then, TCGA datasets were used to validate the results of our meta-analysis. Results. In all, seventeen studies involving 1650 patients were included in this meta-analysis. Pooled results showed that high expression of SPRY4-IT1 was significantly correlated with poor OS ( HR = 1.96 , 95% confidence interval CI = 1.47 ‐ 2.62 , P < 0.001 ) in cancer patients. Furthermore, exploration of TCGA dataset further validated that SPRY4-IT1 was aberrantly expressed in various cancers, which partially confirmed our results in this meta-analysis. Conclusions. The present systematic review and meta-analysis implicated that the aberrant expressions of lncRNA SPRY4-IT1 were strongly associated with clinical survival outcomes in various cancers and therefore might serve as a promising biomarker for predicting prognosis of human cancers.

Download Full-text

Clinical Prognostic Value of Metastasis-Associated Lung Adenocarcinoma Transcript 1 in Various Human Cancers: An Updated Meta-Analysis

The International Journal of Biological Markers ◽

10.5301/jbm.5000185 ◽

2016 ◽

Vol 31 (2) ◽

pp. 173-182 ◽

Cited By ~ 4

Author(s):

Yang Li ◽

Ze Yang ◽

Xiaoya Wan ◽

Jianguo Zhou ◽

Yu Zhang ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Prognostic Value ◽

Meta Analysis ◽

Small Sample ◽

Assay Method ◽

Cochrane Library ◽

Malignant Neoplasms ◽

Tumor Type ◽

Free Survival ◽

Human Cancers

Background Many studies have investigated the prognostic value of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in human cancers. However, these studies were often limited by small sample sizes. Therefore, we performed this updated meta-analysis to summarize the potential value of MALAT1 as a biomarker for early treatment and to predict survival in various human malignant neoplasms, through the inclusion of the latest literature and improved methodology. Methods Twelve eligible articles were systematically obtained from PubMed, Medline, Embase, Web of Science, China National Knowledge Infrastructure and the Cochrane Library, from inception up to June 30, 2015. Survival was assessed using pooled hazard ratios (HRs) and 95% confidence intervals (95% CIs). Results By combining the results of 12 studies, we found elevated MALAT1 expression was associated with poor survival in most cancers, with a pooled HR of 1.90 (95% CI, 1.56-2.30) for overall survival (OS) and 3.06 (95% CI, 2.06-4.56) for recurrence-free survival/disease-free survival. Subgroup analyses according to ethnicity, tumor type, assay method, sample size, HR-calculation method and analysis type did not affect the predictive role of MALAT1 for OS in various cancer types. Further, by combining results from studies that used multivariate analyses, we found elevated MALAT1 was an independent prognostic factor for OS (HR = 1.98; 95% CI, 1.58-2.48). Conclusions MALAT1 could serve as a potential prognostic biomarker in various cancers and may be a potential therapeutic target for the treatment and early detection of recurrence.

Download Full-text

Prognostic Significance of Pretreatment Albumin to Alkaline Phosphatase Ratio in Human Cancers: A Meta-Analysis

10.21203/rs.3.rs-34796/v1 ◽

2020 ◽

Author(s):

Yanwen Wang ◽

Yuwen Sun ◽

Wenying Xu ◽

Yan Wang

Keyword(s):

Alkaline Phosphatase ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Prognostic Significance ◽

Disease Free Survival ◽

Progression Free Survival ◽

Cancer Specific Survival ◽

Free Survival ◽

Human Cancers

Abstract Purpose: To investigate the prognostic value of pretreatment albumin to alkaline phosphatase ratio (AAPR) in human cancers.Methods: Several electronic databases were searched up to Jan 4, 2020 for relevant studies. The prognostic value of AAPR were assessed by pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs). The endpoint events included the overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS) and progression-free survival (PFS).Results: A total of 15 articles involving 20 studies with 6062 cancer patients were included. Our results proved that low pretreatment AAPR was related with poor OS (HR=1.83, 95% CI: 1.66-2.02; P＜0.001), DFS (HR=1.97, 95% CI: 1.49-2.61; P＜0.001), CSS (HR=1.88, 95% CI: 1.37-2.56; P＜0.001) and PFS (HR=1.74, 95% CI: 1.24-2.43; P=0.001). In addition, the significant correlation between pretreatment AAPR and OS was not affected by the treatment strategy and tumor pathological type.Conclusion: Low pretreatment AAPR is related to poor prognosis in human cancers, and AAPR could be served as a promising prognostic indicator in cancer patients.

Download Full-text

HOTAIR as a Prognostic Predictor for Diverse Human Cancers: A Meta- and Bioinformatics Analysis

Cancers ◽

10.3390/cancers11060778 ◽

2019 ◽

Vol 11 (6) ◽

pp. 778 ◽

Cited By ~ 3

Author(s):

Halil Ibrahim Toy ◽

Didem Okmen ◽

Panagiota I. Kontou ◽

Alexandros G. Georgakilas ◽

Athanasia Pavlopoulou

Keyword(s):

Overall Survival ◽

Cancer Patients ◽

Bioinformatics Analysis ◽

Meta Analysis ◽

Disease Free Survival ◽

Progression Free Survival ◽

Predictive Biomarker ◽

Free Survival ◽

Human Cancers ◽

Potential Biomarker

Several studies suggest that upregulated expression of the long non-coding RNA HOX transcript antisense RNA (HOTAIR) is a negative predictive biomarker for numerous cancers. Herein, we performed a meta-analysis to further investigate the prognostic value of HOTAIR expression in diverse human cancers. To this end, a systematic literature review was conducted in order to select scientific studies relevant to the association between HOTAIR expression and clinical outcomes, including overall survival (OS), recurrence-free survival (RFS)/disease-free survival (DFS), and progression-free survival (PFS)/metastasis-free survival (MFS) of cancer patients. Collectively, 53 eligible studies including a total of 4873 patients were enrolled in the current meta-analysis. Pooled hazard ratios (HRs) with their corresponding 95% confidence intervals (CIs) were calculated to assess the relationship between HOTAIR and cancer patients’ survival. Elevated HOTAIR expression was found to be significantly associated with OS, RFS/DFS and PFS/MFS in diverse types of cancers. These findings were also corroborated by the results of bioinformatics analysis on overall survival. Therefore, based on our findings, HOTAIR could serve as a potential biomarker for the prediction of cancer patient survival in many different types of human cancers.

Download Full-text

The prognostic relevance of 14-3-3 expression in cancers: a meta-analysis

Journal of the Pakistan Medical Association ◽

10.47391/jpma.03-402 ◽

2021 ◽

pp. 1-9

Author(s):

Caihong Li ◽

Honglan Zhu ◽

Changlu Liu ◽

Ya Liu ◽

Ting Huang ◽

...

Keyword(s):

Cancer Patients ◽

Meta Analysis ◽

Disease Free Survival ◽

Size Analysis ◽

Tumor Type ◽

Cancer Specific Survival ◽

Free Survival ◽

Hazard Ratios ◽

Prognostic Importance ◽

Patient Prognosis

AbstractObjective: A number of recent clinical studies have identified a relationship between elevated expressions of 14-3-3 and poorer patient prognosis in the context of several cancers. The present meta-analysis was therefore conducted to gain an enhanced understanding of the prognostic importance of 14-3-3 levels in cancer patients. Methods: Two reviewers independently systematically reviewed the Web of Science, Embase, and PubMed databases to identify published, suitable studies through October 2019. The correlation between the level of 14-3-3 and cancer patient survival were assessed based upon pooled HR (hazard ratios) and 95% CI (confidence intervals) derived from chosen studies. Results: In total we were able to identify 22 eligible studies that had enrolled 2676 patients in the present meta-analysis. Assessment of these studies revealed that elevated 14-3-3 level correlated significantly with poorer OS (overall survival) (HR : 1.93, 95% CI : 1.42-2.61) in cancer patients. This was true even when studies were analyzed in subgroups according to tumor type, sample size, analysis type, and method of HR determination. With respect to disease-free survival (DFS), the pooled HR for cancer patients expressing high levels of 14-3-3 was 1.89 (95% CI: 1.56-2.30). Patients with elevated 14-3-3 expression also exhibited reduced CSS (cancer-specific survival) (HR: 3.47, 95% CI: 2.12-5.69).Conclusions: The outcomes indicate that higher level of 14-3-3 correlates with poorer patient prognosis in a range of cancer types.Keywords: Meta-analysis, Prognosis, 14-3-3 Proteins C Continuous...

Download Full-text

Prognostic Role of microRNA-155 in Various Carcinomas: Results from a Meta-Analysis

Disease Markers ◽

10.1155/2013/856750 ◽

2013 ◽

Vol 34 (6) ◽

pp. 379-386 ◽

Cited By ~ 12

Author(s):

Jing He ◽

Fengmei Zhang ◽

Ying Wu ◽

Wei Zhang ◽

Xiaoli Zhu ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Statistical Significance ◽

Prognostic Role ◽

Free Survival ◽

Hazard Ratios ◽

The Relationship

BACKGROUND: Recent studies have shown that microRNAs (miRNA) have prognostic values in cancers. This meta-analysis seeks to summarize the global predicting role of miR-155 for survival in patients with a variety of carcinomas.METHODS: Eligible studies were identified through multiple search strategies. Data were extracted from studies investigating the relationship between miR-155 expression and survival in cancer patients. Combined hazard ratios (HRs) of miR-155 for outcome were analyzed.RESULTS: A total of 16 studies dealing with various carcinomas were included for this meta-analysis. For overall survival, higher miR-155 expression could significantly predict worse outcome with the pooled HR of 2.057 (95% CI: 1.392–3.039). For relapse or progress-free survival, elevated miR-155 was also a significant predictor, with a combined HR of 1.918 (95% CI: 1.311–2.806,). In addition, subgroup analysis showed that higher expression of miR-155 had the trends to predict worse outcome in lung cancer. However, the HRs did not reach the statistical significance.CONCLUSION: Our findings suggest that miR-155 detection has a prognostic value in cancer patients. Regularly measuring miR-155 expression may be useful in clinical practice.

Download Full-text

Prognostic value of pretreatment platelet counts in lung cancer: a systematic review and meta-analysis

10.21203/rs.2.16573/v5 ◽

2020 ◽

Author(s):

Yuan Yuan ◽

Hai Zhong ◽

Liang Ye ◽

Qian Li ◽

rong su Fang ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Publication Bias ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Free Survival ◽

Lung Cancer Patients ◽

Platelet Counts

Abstract Background : The prognostic value of elevated pretreatment platelet counts remains controversial in lung cancer patients. We performed the present meta-analysis to determine its precise role in these patients. Methods: We employed a multiple search strategy in the PubMed, EMBASE and Cochrane Library databases to identify eligible studies. Disease-free survival (DFS)/progression-free survival (PFS)/time to progression (TTP) and overall survival (OS) were used as outcomes with hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity among the studies and publication bias were also evaluated. Results : A total of 40 studies including 16696 lung cancer patients were eligible for the analysis. Overall, the pooled analysis showed that compared with normal platelet counts, elevated pretreatment platelet counts were associated with poorer OS (HR= 1.54, 95% CI: 1.37-1.72, P<0.001) and poorer DFS/PFS/TTP (HR=1.62, 95% CI: 1.33-1.98, P<0.001) in patients with lung cancer. In subgroup analyses, elevated pretreatment platelet counts were also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias. Conclusions : This meta-analysis revealed that elevated pretreatment platelet counts were an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large-scale prospective studies and a validation study are warranted.

Download Full-text

Prognostic value of platelet count in lung cancer: a systematic review and meta-analysis

10.21203/rs.2.16573/v1 ◽

2019 ◽

Author(s):

Yuan Yuan ◽

Hai Zhong ◽

Liang Ye ◽

Qian Li ◽

Rong Su Fang ◽

...

Keyword(s):

Lung Cancer ◽

Platelet Count ◽

Cancer Patients ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Free Survival ◽

Lung Cancer Patients ◽

Pubmed Database

Abstract Background : The prognostic value of pretreatment elevated platelet count remains controversial in lung cancer patients. We performed the present meta-analysis to determine the precise role of it in these patients.Methods: We performed a multiple search strategy in PubMed database, EMBASE and Cochrane Library to identify eligible studies. Disease-free survival (DFS) /Progress-free survival (PFS)/Time to progress(TTP) and Overall survival (OS) were used as outcomes with hazard ratio (HR) and its 95% confidence intervals (CIs). Heterogeneity among studies and publication bias were also evaluated.Results : A total of 39 studies including 16696 lung cancer patients were eligible in the analysis. Overall, the pooled analysis showed that pretreatment elevated platelet count was associated with poorer OS (HR= 1.47, 95%CI: 1.31-1.66, P<0.001) and poorer DFS/PFS/TTP ((HR=1.63, 95%CI: 1.28-2.09, P<0.001) in patients with lung cancer compared with normal platelet count. In subgroup analyses, pretreatment elevated platelet count was also associated with poorer OS and DFS/PFS/TTP in most subgroups. There was no evidence of publication bias.Conclusions : This meta-analysis revealed that pretreatment elevated platelet count was an independent predictor of OS and DFS/PFS/TTP in lung cancer patients. Large scale prospective studies and a validation study are warranted.

Download Full-text

MiR-24-3p and various cancers: From a meta-analysis view

10.21203/rs.3.rs-42539/v1 ◽

2020 ◽

Author(s):

He Wang ◽

Chunyang Chen ◽

Weijie Zhang ◽

Keke Ding ◽

Jianquan Hou

Keyword(s):

Overall Survival ◽

Fixed Effects ◽

Prognostic Value ◽

Meta Analysis ◽

Disease Free Survival ◽

Cochrane Library ◽

Fixed Effects Model ◽

Odds Ratios ◽

Free Survival ◽

Expression Levels

Abstract Background: A growing number of researches suggests that microRNAs (miRNAs) as oncogene or tumor suppressor genes play a fundamental role in various kinds of cancers. Among them, miR-24-3p, as a star molecule, is widely studied. However, the prognostic value of miR-24-3p is unclear and controversial. We conducted this meta-analysis to evaluate the prognostic value of miR-24-3p in a variety of cancers by integrated existing articles from four databasesMethods: PubMed, Embase, Web of Science, and Cochrane Library (last update in March 2020) were searched for approach literature. Hazard ratios (HRs) and odds ratios (ORs) were used to evaluate the association between miR-24-3p expression levels and prognostic value or clinicopathological characteristics, respectively.Results: A total of 15 studies from 14 literature were finally qualified and concluded in the present meta-analysis. A significantly worse overall survival was observed in higher expression of miR-24-3p cancer group for OS(Overall survival) of log rank tests and cox multivariate regression by fixed effects model. Also, we found a significant correlation between elevated miR-24-3p levels to RFS (Recurrence-free survival) and DFS(Disease free survival). In addition, the pooled odds ratios (ORs) showed that evaluated miR-24-3p was also associated with the larger tumor size (≥5cm) and advanced TNM stage (Ⅲ and Ⅳ).Conclusion: Built on the above findings, elevated expression levels of miR-24-3p may serve as a promising biomarker used to predict the worse prognosis of cancer patients.

Download Full-text

Prognostic value of lncRNA SNHG20 as a biomarker in human cancers: a systematic review and meta-analysis

10.21203/rs.3.rs-25239/v1 ◽

2020 ◽

Author(s):

Yongfeng Li ◽

Xinmiao Rui ◽

Daobao Chen ◽

Haojun Xuan ◽

Hongjian Yang ◽

...

Keyword(s):

Noncoding Rna ◽

Prognostic Value ◽

Meta Analysis ◽

Estimation Method ◽

Clinicopathological Characteristics ◽

Clinicopathological Features ◽

Tnm Stage ◽

Clinical Value ◽

Human Cancers ◽

Trim And Fill

Abstract Background: Long noncoding RNA small nucleolar RNA host gene 20 (SNHG20) is a novel oncogene and dysregulated in a variety of human cancers. It has been revealed to be associated with the clinicopathological features and prognosis. However, the prognostic value of SNHG20 in various cancers remains unclear. Therefore, we performed this meta-analysis to evaluate the relationship between SNHG20 expression and clinical outcomes in human cancers.Methods: Comprehensive literature search was performed in PubMed, Web of Science, CNKI and Wangfang databases, and eligible studies were obtained according to the inclusion and exclusion criteria. The pooled hazard ratios (HRs) and odds ratios (ORs) were applied to assess the clinical value of SNHG20 expression for overall survival (OS) and clinicopathological features.Results: A total of 16 articles including 1190 cancer patients were included in the study. The pooled results demonstrated that evaluated SNHG20 expression was positively related to a poorer OS of cancers (HR=2.36, 95%CI: 1.85-2.87, P<0.001). Subgroup analysis revealed that SNHG20 overexpression was closely related to the low OS of patients with the digestive system cancer (HR=2.92, 95%CI: 1.96-3.88, P<0.001), sample size >80 (HR=2.42, 95%CI: 1.69-3.14, P<0.001), direct HR estimation method (HR=2.65, 95%CI: 1.78-3.52, P<0.001), and median ratio as cut-off value (HR=2.21, 95%CI: 1.60-2.83, P<0.001). In addition, the pooled data also showed that SNHG20 was positively linked to lymph node metastasis (LNM) (OR=1.65, 95%CI: 1.21-2.26, P=0.002), distant metastasis (DM) (OR=1.76, 95%CI: 1.10-2.83, P=0.02), and advanced TNM stage (OR=1.79, 95%CI: 1.34-2.39, P<0.001). Moreover, the results of the trim and fill analysis confirmed the reliability of our finding. Conclusions: Upregulation of SNHG20 was associated with advanced TNM stage, worse LNM and DM, and shorter OS, suggesting that SNHG20 may serve as a biomarker for prognosis and clinicopathological characteristics in human cancers.

Download Full-text